EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A cost‐effectiveness analysis of behavioural, pharmacological, and surgical obesity treatments in Canada

Nisha Gupta iD, Allie Babyak, Areni Chorbajian, Vanessa Tardio iD, Jeromie Ballreich, Kaberi Dasgupta iD

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16627 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Nisha Gupta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, McGill University, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Bariatric Surgery, Obesity, Morbid, Anti-Obesity Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fonds de Recherche du Québec - Santé.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Effective weight management pharmacotherapies are a new alternative to bariatric surgery or health behaviour intervention (HBI) alone. Comparative cost‐effectiveness evaluations can guide decision‐making. We aimed to evaluate the cost‐effectiveness of sleeve gastrectomy (SG), Roux‐en‐Y gastric bypass (RYGB), semaglutide, tirzepatide, and HBI compared to no treatment in preventing cardiometabolic complications among Canadian adults with class III obesity. Materials and Methods We developed a cohort‐based Markov model with a 40‐year time horizon. We examined cardiometabolic complications in 40‐year‐olds with class III obesity (BMI ≥40 kg/m 2 ) without type 2 diabetes or cardiovascular disease at baseline. We compared SG, RYGB, semaglutide 2.4 mg, tirzepatide 15 mg, HBI, and no treatment. We obtained data on treatment effects, probabilities, utilities, and costs from published literature. We expressed effectiveness in quality‐adjusted life years (QALYs) and estimated costs from a Canadian public payer perspective. Outcomes included incremental cost‐effectiveness ratios (ICERs) evaluated at a CAD $50 000/QALY willingness‐to‐pay threshold.

Results

RYGB and HBI were cost‐effective strategies. HBI was cost‐effective versus no treatment (ICER $14 279/QALY). RYGB demonstrated the highest QALYs (20.20) and was the most cost‐effective strategy versus tirzepatide (ICER $44 667/QALY). Semaglutide and SG were strongly dominated due to higher costs and lower effectiveness. Tirzepatide was extendedly dominated by RYGB. Sensitivity analyses confirmed these findings and showed that lower drug prices could improve pharmacotherapy cost‐effectiveness.

Conclusions

RYGB and HBI are cost‐effective for managing class III obesity. While RYGB provided the greatest health gains, access remains limited. Neither pharmacotherapy was cost‐effective at current prices. Lower drug prices could significantly improve pharmacotherapy cost‐effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bariatric SurgeryObesity, MorbidAnti-Obesity AgentsHumansCost-Benefit AnalysisCanadaAdultQuality-Adjusted Life YearsFemaleMaleGastrectomyGastric BypassGlucagon-Like PeptidesMarkov ChainsCost-Effectiveness AnalysisGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

GLP‐1antiobesity drugbariatric surgerycost‐effectivenesshealth economicsweight management

Substanzen

Glucagon-Like PeptidesAnti-Obesity AgentsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Department of Medicine, McGill University, Montreal, Quebec, Canada.
  • Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
  • Department of Health Policy and Management, Johns Hopkins University, Baltimore, Maryland, USA.
  • Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.

ORCID-Profile: Nisha Gupta, Vanessa Tardio, Kaberi Dasgupta

Förderung

  • Fonds de Recherche du Québec - Santé

Zitieren

APA

Gupta, N., Babyak, A., Chorbajian, A., Tardio, V., Ballreich, J., & Dasgupta, K. (2025). A cost‐effectiveness analysis of behavioural, pharmacological, and surgical obesity treatments in Canada. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16627

Vancouver

Gupta N, Babyak A, Chorbajian A, Tardio V, Ballreich J, Dasgupta K. A cost‐effectiveness analysis of behavioural, pharmacological, and surgical obesity treatments in Canada. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16627

BibTeX
@article{Gupta2025,
  author = {Gupta, Nisha and Babyak, Allie and Chorbajian, Areni and Tardio, Vanessa and Ballreich, Jeromie and Dasgupta, Kaberi},
  title = {A cost‐effectiveness analysis of behavioural, pharmacological, and surgical obesity treatments in Canada},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16627}
}
Kostenlos starten →